VIELA BIO

A clinical-stage biotechnology company pioneering and advancing treatments for severe inflammation and autoimmune diseases by selectively targeting shared critical pathways that are the root cause of disease

Learn More

Our Portfolio

Viela Bio is building a portfolio of innovative biologics that either are first in class or have the potential to be best in class

Our Team

Viela Bio is led by a team of motivated industry experts, aiming to make a difference for inflammation and autoimmunity patients

Our Recent News

Viela Bio Announces Late-Breaking Abstract Acceptance for VIB4920 at the 2018 ACR/ARHP Annual Meeting

| Company General News | No Comments
VIB4920 demonstrated proof-of-concept in a Phase 1b multiple-ascending dose study October 19, 2018 07:00 EST--Viela Bio, Gaithersburg, MD, heads to the 2018 American College of Rheumatology / Association of Rheumatology…

Viela Bio Announces Start of Clinical Trial

| Company General News | No Comments
Viela Bio Announces Start of Clinical Trial August 23, 2018--Gaithersburg, Maryland--Viela Bio announced the start of a phase 1, first-in-human clinical trial of VIB9600, which is being developed for the…

Why A Spin-off Is A Win-Win For Big Pharma And Startups

| Magazine Articles | No Comments
Why A Spin-off Is A Win-Win For Big Pharma And Startups Source: Life Science Leader By Gail Dutton, Contributing Writer Follow Me On Twitter @GailLdutton When Viela Bio spun out of MedImmune in…

Viela Bio Spins Out of MedImmune

| Company General News | No Comments
Viela Bio team will focus on developing medicines for severe autoimmune diseases by targeting critical pathways that are the root cause of disease Gaithersburg, MD, February 28, 2018 – Viela…